Study (year)

N (% of female)

Age (SD)

Treatment

Dose (mg)

Frequency (dose/day)

Duration

Aisen et al. (2002)

19 (47.4)

21 (38.1)

74 (8.7)

73 (9.1)

Placebo

Nimesulide

100

2

2

84

84

Aisen et al. (2003)

111 (55.9)

118 (48.3)

122 (54.9)

73.8 (8.0)

74.1 (7.8)

73.7 (7.2)

Placebo

Naproxen

Rofecoxib

220

25

2

2

1

365

365

365

Thal et al. (2005)

732 (31.1)

723 (34.3)

74.8 (6.0)

75.1 (6.0)

Placebo

Rofecoxib

25

1

1

1460

1460

Pasqualetti et al. (2009)

66 (65.0)

66 (61.0)

74.0 (7.8)

73.7 (7.3)

Placebo

Ibuprofen

400

2

2

365

365

Babiloni et al. (2009)

17 (70.8%)

18 (78.2%)

74 (6.5)

75.6 (6.7)

Placebo

Ibuprofen

400

2

2

365 days

Jong et al. (2008)

19 (76.0)

19 (53.8)

72.2 (9)

72.7 (6.9)

Placebo

Indomethacin

100

1

1

365

365

Green et al. (2009)

809 (52.5)

840 (49.4)

74.7 (8.4)

74.6 (8.5)

Placebo

Tarenflurbil

800

2

2

540

540

Ryan et al. (2004)

92525 (56.4)

9589 (56.4)

65 - 73 years (median age group)

Placebo

Asprin

100

1

1

1716

1716

Wilcock et al. (2008)

46 (41.0)

48 (50.0)

75.6 (6.8)

75.7 (7.6)

Placebo

Tarenflurbil

800

2

2

365

365

Jeannie et al. (2011)

722 (NR)

722 (NR)

1084 (NR)

NR

NR

NR

Placebo

Naproxen

Celecoxib

220

200

1

1

1

1460

1460

1460